Safety, efficacy, and tolerability of Sofosbuvir and Ribavirin in management of recurrent hepatitis c virus genotype 4 after living donor liver transplant in Egypt: What have we learned so far?

Hepatitis Monthly

Volumn 16, Issue 5, 2016, Pages

  Dabbous, Hany M ^a   Montasser, Iman F ^a   Sakr, Mohamed A ^a   Refai, Rasha ^a   Sayam, Moataz ^a   Abdelmonem, Ahmed ^a   Sayed, Hany ^a   Abdelghafar, Mohamed F ^a   Bahaa, Mohamed ^a   Elmeteini, Mahmoud S ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Genotype 4; Liver transplant; Sofosbuvir

Indexed keywords

AMINOTRANSFERASE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; DASABUVIR; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; LEDIPASVIR; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS;

ACUTE KIDNEY FAILURE; ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EGYPT; ELASTOGRAPHY; FEMALE; FIBROSIS; GLOMERULUS FILTRATION RATE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LEUKOCYTE COUNT; LIVER DISEASE; LIVER GRAFT; MALE; MIDDLE AGED; NEUTROPHIL COUNT; PANCYTOPENIA; REPERFUSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNSPECIFIED SIDE EFFECT;

EID: 84990303170     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.35339     Document Type: Article

References (13)

1. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35(3):680-7. doi: 10.1053/jhep.2002.31773. [PubMed: 11870384].
2. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122(4):889-96. [PubMed: 11910340].
3. Blasco A, Forns X, Carrion JA, Garcia-Pagan JC, Gilabert R, Rimola A, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology. 2006;43(3):492-9. doi: 10.1002/hep.21090. [PubMed: 16496308].
4. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41(5):830-6. doi: 10.1016/j.jhep.2004.06.029. [PubMed: 15519657].
5. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008;8(3):679-87. doi: 10.1111/j.1600-6143.2007.02126.x. [PubMed: 18294165].
6. Gambato M, Lens S, Navasa M, Forns X. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. J Hepatol. 2014;61(1):S120-31. doi: 10.1016/j.jhep.2014.07.020. [PubMed: 25443340].
7. Charlton M, Gane E, Manns MP, Brown RJ, Curry MP, Kwo PY, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148(1):108-17. doi: 10.1053/j.gastro.2014.10.001. [PubMed: 25304641].
8. Jensen DM, O’Leary JG, Pockros PJ, Sherman KE, Kwo PY, Mailliard ME, et al. Safetyandefficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort. USA: WILEY-BLACKWELL; 2014.
9. Aasld Idsa Hcv Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932-54. doi: 10.1002/hep.27950. [PubMed: 26111063].
10. Reddy KR, Everson GT, Flamm SL, Denning JM, Arterburn S, Brandt-Sarif T. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study. Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
11. Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-1 study. Proceedings of the 50th Annual Meeting of the European Association for the Study of the Liver (EASL).
12. Esmat GE, Omar RF, Khairy M, Doss W, Shiha G, Hassany M. Sofosbuvir plus ribavirin in the treatment of Egyptian patients with chronic genotype 4 HCV infection. Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
13. Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015;61(5):1485-94. doi: 10.1002/hep.27681. [PubMed: 25557906].